A previous study demonstrates that newly diagnosed RUNX1::RUNX1T1 AML patients treated with VEN + HMA achieve a significantly lower CRc rate compared to the standard “7 + 3” regimen (27.8% vs. 61.8%, p = 0.02). The gene discussed is RUNX1; the disease is acute myeloid leukemia.